142 related articles for article (PubMed ID: 31343829)
1. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
[No Abstract] [Full Text] [Related]
2. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
3. Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI-Resistant Patients.
Kaira K; Kagamu H
J Thorac Oncol; 2019 Jun; 14(6):e135-e136. PubMed ID: 31122569
[No Abstract] [Full Text] [Related]
4. Immune checkpoint therapy in proteinuric kidney disease.
Takenaka T; Kawai Y; Amano T
Eur J Cancer; 2018 May; 95():120-122. PubMed ID: 29530540
[No Abstract] [Full Text] [Related]
5. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
Sari M; Saip P
J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
[TBL] [Abstract][Full Text] [Related]
6. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
7. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M
Intern Med; 2019; 58(10):1479-1484. PubMed ID: 31092773
[TBL] [Abstract][Full Text] [Related]
8. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
Hu S; Li Q; Peng W; Feng C; Zhang S; Li C
J Thorac Oncol; 2018 May; 13(5):e72-e74. PubMed ID: 29703539
[No Abstract] [Full Text] [Related]
9. [Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.].
Cortinovis DL
Recenti Prog Med; 2018 Mar; 109(3):197e-201e. PubMed ID: 29565054
[TBL] [Abstract][Full Text] [Related]
10. Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.
Kuraoka N; Hara K; Terai S; Yatabe Y; Horio Y
Endoscopy; 2018 Sep; 50(9):E259-E261. PubMed ID: 29969801
[No Abstract] [Full Text] [Related]
11. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab.
Otsubo K; Nakatomi K; Furukawa R; Ashida K; Yoneshima Y; Nakanishi Y; Okamoto I
Ann Oncol; 2017 Dec; 28(12):3106-3107. PubMed ID: 28945828
[No Abstract] [Full Text] [Related]
12. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
13. Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report.
Pluvy J; Brosseau S; Stelianides S; Danel C; Nguenang M; Khalil A; Crestani B; Zalcman G; Gounant V
BMC Pulm Med; 2019 Jan; 19(1):12. PubMed ID: 30634951
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
15. Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis.
Kenzaka T; Miyoshi K; Nakaji H
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30317212
[No Abstract] [Full Text] [Related]
16. Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Nakahara Y; Fukui T; Shirasawa M; Harada S; Kusuhara S; Takakura A; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N; Inukai M; Sekiguchi T; Naoki K
Intern Med; 2018 Nov; 57(21):3149-3152. PubMed ID: 29877291
[TBL] [Abstract][Full Text] [Related]
17. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.
Wei Q; Zhang J; Chen D; Li S; Liu Y
Lung Cancer; 2020 Oct; 148():175-176. PubMed ID: 32883519
[No Abstract] [Full Text] [Related]
18. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
19. [Application of radiomics captured from CT to predict the EGFR mutation status and TKIs therapeutic sensitivity of advanced lung adenocarcinoma].
Yang CS; Chen WD; Gong GZ; Li ZJ; Qiu QT; Yin Y
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):282-287. PubMed ID: 31014053
[No Abstract] [Full Text] [Related]
20. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
[No Abstract] [Full Text] [Related]
[Next] [New Search]